文献速递心力衰竭与心肌病

烟酰胺核糖在扩张型心肌病小鼠模型中保护心脏功能

Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy.
PubMed 文献 · Circulation · 2017-12-07

该研究探讨了心力衰竭中心肌NAD+稳态的改变,并评估烟酰胺核糖补充对两种小鼠模型心脏功能的影响。发现衰竭心脏中NAD+水平下降30%,烟酰胺核糖补充可稳定心肌NAD+水平,减轻扩张型心肌病小鼠的心力衰竭发展,对主动脉缩窄模型部分有效。

要点

  • 衰竭心脏中NAD+水平下降30%,烟酰胺磷酸核糖转移酶表达降低。
  • 烟酰胺核糖补充可稳定心肌NAD+,减轻扩张型心肌病小鼠心力衰竭。
  • 烟酰胺核糖治疗增加3种代谢物,可作为治疗验证生物标志物。

核心结论

  • 烟酰胺核糖是能量效率最高的NAD前体,可能用于治疗心力衰竭,尤其在扩张型心肌病中。

研究设计与样本

  • 研究量化了人衰竭心脏和小鼠扩张型心肌病及主动脉缩窄模型心脏中NAD+生物合成酶的表达。
  • 研究了NAD+前体补充对两种小鼠模型心脏功能的影响。

主要发现

  • 小鼠扩张型心肌病和主动脉缩窄衰竭心脏中NAD+水平下降30%。
  • 烟酰胺磷酸核糖转移酶表达降低,烟酰胺核糖激酶2表达增加,扩张型心肌病中增加40倍,主动脉缩窄中增加4倍。
  • 人衰竭心脏活检中观察到类似转变。
  • 烟酰胺核糖有效挽救FK866抑制烟酰胺磷酸核糖转移酶后的NAD+合成,并刺激心肌细胞糖酵解。
  • 烟酰胺核糖补充减轻小鼠心力衰竭发展,扩张型心肌病中更显著,主动脉缩窄中部分有效。

临床怎么用

  • 烟酰胺核糖补充可能作为心力衰竭尤其是扩张型心肌病的治疗策略。
  • 心肌烟酸腺嘌呤二核苷酸、甲基烟酰胺和N1-甲基-4-吡啶酮-5-甲酰胺水平可作为治疗验证生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myocardial metabolic impairment is a major feature in chronic heart failure. As the major coenzyme in fuel oxidation and oxidative phosphorylation and a substrate for enzymes signaling energy stress and oxidative stress response, nicotinamide adenine dinucleotide (NAD+) is emerging as a metabolic target in a number of diseases including heart failure. Little is known on the mechanisms regulating homeostasis of NAD+ in the failing heart. METHODS: To explore possible alterations of NAD+ homeostasis in the failing heart, we quantified the expression of NAD+ biosynthetic enzymes in the human failing heart and in the heart of a mouse model of dilated cardiomyopathy (DCM) triggered by Serum Response Factor transcription factor depletion in the heart (SRFHKO) or of cardiac hypertrophy triggered by transverse aorta constriction. We studied the impact of NAD+ precursor supplementation on cardiac function in both mouse models. RESULTS: We observed a 30% loss in levels of NAD+ in the murine failing heart of both DCM and transverse aorta constriction mice that was accompanied by a decrease in expression of the nicotinamide phosphoribosyltransferase enzyme that recycles the nicotinamide precursor, whereas the nicotinamide riboside kinase 2 (NMRK2) that phosphorylates the nicotinamide riboside precursor is increased, to a higher level in the DCM (40-fold) than in transverse aorta constriction (4-fold). This shift was also observed in human failing heart biopsies in comparison with nonfailing controls. We show that the Nmrk2 gene is an AMP-activated protein kinase and peroxisome proliferator-activated receptor α responsive gene that is activated by energy stress and NAD+ depletion in isolated rat cardiomyocytes. Nicotinamide riboside efficiently rescues NAD+ synthesis in response to FK866-mediated inhibition of nicotinamide phosphoribosyltransferase and stimulates glycolysis in cardiomyocytes. Accordingly, we show that nicotinamide riboside supplementation in food attenuates the development of heart failure in mice, more robustly in DCM, and partially after transverse aorta constriction, by stabilizing myocardial NAD+ levels in the failing heart. Nicotinamide riboside treatment also robustly increases the myocardial levels of 3 metabolites, nicotinic acid adenine dinucleotide, methylnicotinamide, and N1-methyl-4-pyridone-5-carboxamide, that can be used as validation biomarkers for the treatment. CONCLUSIONS: The data show that nicotinamide riboside, the most energy-efficient among NAD precursors, could be useful for treatment of heart failure, notably in the context of DCM, a disease with few therapeutic options.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Diguet N, Trammell SAJ, Tannous C, et al. Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. Circulation. 2017. PMID: 29217642. doi:10.1161/CIRCULATIONAHA.116.026099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。